Form 4: CareDx Director Suresh Gunasekaran Receives RSU Grant

Director Suresh Gunasekaran was granted 9,795 restricted stock units in CareDx, Inc. as part of standard equity compensation.

Summary

• Director Suresh Gunasekaran acquired 9,795 restricted stock units (RSUs) of CareDx, Inc. common stock.
• The transaction occurred on June 12, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership is 37,248 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the reporting person's continuous service to the company.

Future Outlook

The RSUs vest 100% on the earlier of the one-year anniversary of the grant or the day immediately before the first Annual Meeting occurring after the grant date, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder value in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-cap healthcare companies.
• The vesting schedule is typical for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 9,795 RSUs on the earlier of the one-year anniversary or the day before the next Annual Meeting.

Key Dates

Keywords

CareDx, CDNA, Form 4, Insider Trading, Equity Compensation, Director